Azetukalner Cuts Seizures Up to 53% in Drug-Resistant Focal Epilepsy in Phase 3 Trial
In the 374-patient X-TOLE2 phase 3 trial, the KV7 opener azetukalner cut focal seizures by a median of 53% at 25 mg versus 10% with placebo.
Summary
About half of people with epilepsy do not achieve long-term seizure freedom with their first medication. This phase 3 trial tested azetukalner, a new drug that opens potassium channels to calm overactive brain cells. It enrolled 374 adults who were still having at least 4 focal seizures a month on 1 to 3 other medications. Over 12 weeks, median seizure frequency fell 10% on placebo, 35% on 15 mg and 53% on 25 mg. More than half of those on 25 mg had at least a 50% drop in seizures, versus about 1 in 5 on placebo. Dizziness, sleepiness, tremor and confusion were the main side effects, and they were more frequent at the higher dose. About 15% of those on 25 mg stopped the drug because of side effects. No deaths occurred.
Detailed Summary
More than 50 million people worldwide are diagnosed with epilepsy, and about half do not achieve long-term seizure freedom with their first medication. Despite more than 30 approved antiseizure medications, many patients cycle through multiple drugs and polytherapy, with higher morbidity, mortality and impaired quality of life. Azetukalner (XEN1101) is a potent KV7 channel opener. It enhances the KV7.2/7.3 potassium current (M-current), an intrinsic brake on neuronal excitability, through a mechanism distinct from existing drugs.
X-TOLE2 was a phase 3, double-blind, placebo-controlled trial at 138 sites across North America, South America, Europe and Asia Pacific, running from November 2022 to February 2026. Of 380 randomized adults, 374 were treated: 125 on placebo, 125 on 15 mg and 124 on 25 mg, taken once daily with the evening meal for 12 weeks with no titration. Participants had focal epilepsy with at least 4 seizures per 28 days despite 1 to 3 stable antiseizure medications. The mean age was 40 and 50.8% were female. The median baseline was 12.75 seizures per month, and participants had previously tried and stopped a median of 5 medications. Randomization was stratified by use of CYP3A4-inducing drugs.
The primary endpoint was met. Median monthly focal seizure frequency fell 10.4% with placebo, 34.5% with 15 mg and 53.2% with 25 mg (both P < .001 vs placebo). The authors describe this as one of the largest placebo-controlled reductions reported in drug-resistant epilepsy. Median weekly frequency was down 45.2% in the 25-mg group in week 1 (P = .001), versus 19.3% with placebo, and the effect deepened to a 70.4% reduction by week 12.
Responder analyses followed the same dose-dependent pattern. A reduction of at least 50% was reached by 20.8% on placebo, 37.6% on 15 mg (OR 2.41, 95% CI 1.35-4.33) and 54.8% on 25 mg (OR 4.96, 95% CI 2.77-8.88). Reductions of at least 75% were reached by 8.0%, 16.8% and 26.6%. Complete seizure freedom over the whole period, counted from day 1 without titration, occurred in 0.8%, 4.0% and 6.5%. In post hoc analysis of the final 4 weeks, seizure freedom rose to 4.0%, 12.8% and 13.7%. Patient-rated improvement on the PGI-C was 26.4% with placebo, 46.4% and 45.2% with the two doses.
Safety followed a dose-dependent pattern. Any adverse event occurred in 62.4% on placebo, 67.2% on 15 mg and 82.3% on 25 mg. Dizziness (31.5% at 25 mg), tremor (12.1%), confusional state (10.5%), aphasia (9.7%), gait disturbance (9.7%) and somnolence (9.7%) were most frequent at the higher dose. Discontinuation for adverse events was 3.2%, 4.8% and 14.5%. Serious adverse events occurred in 2.4%, 3.2% and 5.6%. There were no deaths and no cardiovascular, skin discoloration or retinal safety signals of concern, though two psychotic events and four non-serious urinary retention events were reported.
The results support azetukalner as a promising option for patients with highly treatment-resistant focal epilepsy, with benefit appearing within a week and no titration needed. Caveats include the short 12-week double-blind window, which says little about long-term durability, and a largely White (81.8%) cohort. The 15-mg dose missed significance at week 1 (P = .08), and several higher-threshold and seizure-freedom analyses were exploratory or post hoc with nominal P values. The tolerability cost at 25 mg, including 78% completion versus 93-95% in the other groups, will matter in real-world use.
Key Findings
- Median monthly focal seizure frequency fell 53.2% with 25-mg azetukalner and 34.5% with 15 mg, versus 10.4% with placebo (both P < .001).
- At least a 50% seizure reduction was achieved by 54.8% on 25 mg (OR 4.96, 95% CI 2.77-8.88), 37.6% on 15 mg (OR 2.41) and 20.8% on placebo.
- Efficacy was rapid: week-1 weekly seizure frequency fell 45.2% on 25 mg versus 19.3% on placebo (P = .001), reaching a 70.4% reduction by week 12.
- Higher thresholds followed the same trend: at least 75% reduction in 26.6% on 25 mg versus 8.0% on placebo, and at least 90% in 12.9% versus 3.2% (nominal P = .01).
- In the final 4 weeks, 100% seizure freedom was reached by 13.7% on 25 mg and 12.8% on 15 mg versus 4.0% on placebo (post hoc, nominal P = .008 and .01).
- Any adverse event occurred in 82.3% on 25 mg versus 62.4% on placebo, led by dizziness (31.5%), tremor (12.1%) and confusional state (10.5%).
- Adverse-event discontinuations were 14.5% on 25 mg, 4.8% on 15 mg and 3.2% on placebo; there were no deaths and no cardiovascular, skin or retinal signals of concern.
Methodology
X-TOLE2 was a phase 3, multicenter, double-blind, placebo-controlled trial at 138 sites. After an 8- to 9.5-week baseline, 374 treated adults with focal epilepsy (at least 4 seizures per 28 days on 1-3 antiseizure medications) were randomized 1:1:1 to placebo, 15 mg or 25 mg azetukalner once daily with the evening meal for 12 weeks, with no titration. Randomization was stratified by CYP3A4-inducer use, and seizures were logged in an electronic diary. The primary endpoint was the median percentage change in monthly seizure frequency, analyzed with a ranked ANCOVA in the modified intent-to-treat population. Key secondary endpoints were tested in a prespecified hierarchy, and 6 of 8 endpoints reached significance. The sample size of at least 360 gave over 90% power.
Study Limitations
The 12-week double-blind period limits conclusions about long-term efficacy and safety, which depend on the open-label extension. The cohort was predominantly White (81.8%) with only 3.7% aged 65 or older, and several higher-threshold and seizure-freedom analyses were exploratory or post hoc with nominal P values. Funding and conflict-of-interest details were not included in the supplied text, so they should be checked in the published paper.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
